These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Individualization of drug dosage by therapeutic monitoring in plasma and the application of pharmacokinetic principles]. Klotz U J Clin Chem Clin Biochem; 1983 Nov; 21(11):649-58. PubMed ID: 6655441 [TBL] [Abstract][Full Text] [Related]
44. Dose-dependence of the apparent half-life of phenytoin in the rat. Vicuna A; Lalka D; duSouich P; Vicuna N; Ludden TM; McLean AJ Res Commun Chem Pathol Pharmacol; 1980 Apr; 28(1):3-11. PubMed ID: 7394315 [TBL] [Abstract][Full Text] [Related]
45. The genetic control of drug oxidation in the liver. Dayer P; Balant L; Fabre J Int J Clin Pharmacol Res; 1983; 3(6):421-5. PubMed ID: 6147316 [TBL] [Abstract][Full Text] [Related]
47. Using pharmacokinetics in drug therapy. VII: Pharmacokinetic factors influencing drug therapy in the aged. Schumacher GE Am J Hosp Pharm; 1980 Apr; 37(4):559-62. PubMed ID: 6990755 [TBL] [Abstract][Full Text] [Related]
48. Prediction of drug oxidation rates in man: lack of correlation with serum gamma-glutamyl transpeptidase and urinary excretion of D-glucaric acid and 6 beta-hydroxycortisol. Smith SE; Rawlins MD Eur J Clin Pharmacol; 1974; 7(1):71-5. PubMed ID: 4153008 [No Abstract] [Full Text] [Related]
49. A new polymorphism of hepatic drug oxidation in man: family studies on rates of formation of antipyrine metabolites. Vessell ES; Penno MB Biochem Soc Trans; 1984 Feb; 12(1):74-8. PubMed ID: 6705993 [No Abstract] [Full Text] [Related]
50. [Dosage of drugs with regard to their distribution volume and biological half-life]. Dahl SG Tidsskr Nor Laegeforen; 1974 Jun; 94(18):1201-2. PubMed ID: 4839999 [No Abstract] [Full Text] [Related]
51. A modern view of pharmacokinetics. Wagner JG J Pharmacokinet Biopharm; 1973 Oct; 1(5):363-401. PubMed ID: 4599379 [No Abstract] [Full Text] [Related]
52. Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy. Chiba K; Ishizaki T; Tabuchi T; Wagatsuma T; Nakazawa Y Obstet Gynecol; 1982 Nov; 60(5):620-6. PubMed ID: 6815599 [TBL] [Abstract][Full Text] [Related]
53. Clinical pharmacokinetics of phenytoin in the dog: a reevaluation. Frey HH; Löscher W Am J Vet Res; 1980 Oct; 41(10):1635-8. PubMed ID: 6784613 [TBL] [Abstract][Full Text] [Related]
54. In vitro hepatic oxidative metabolism of antipyrine, phenytoin and phenylbutazone in uraemic rabbits. Van Peer AP; Belpaire FM; Bogaert MG J Pharm Pharmacol; 1980 Feb; 32(2):135-6. PubMed ID: 6103036 [No Abstract] [Full Text] [Related]
55. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Eichelbaum M Clin Pharmacokinet; 1982; 7(1):1-22. PubMed ID: 7042170 [No Abstract] [Full Text] [Related]
57. The Upjohn Award Lecture 1981/La Conférence Upjohn 1981. The metabolism of xenobiotics in different populations. Kalow W Can J Physiol Pharmacol; 1982 Jan; 60(1):1-12. PubMed ID: 7039786 [No Abstract] [Full Text] [Related]
58. Utility of clinical chemical determinations of drug concentrations in biological fluids. Vessell ES; Passananti GT Clin Chem; 1971 Sep; 17(9):851-66. PubMed ID: 4105897 [No Abstract] [Full Text] [Related]
59. Lack of stimulation of antipyrine and phenytoin metabolism by lithium carbonate in man. Perrild H; Hansen JM; Skovsted L; Simonsen K; Hegedüs L; Christensen LK Acta Pharmacol Toxicol (Copenh); 1983 Apr; 52(4):315-7. PubMed ID: 6408891 [No Abstract] [Full Text] [Related]
60. Significance of apparent half-lives of a metabolite with a higher elimination rate than its parent drug. Vree TB; Hekster CA; van der Kleijn E Drug Intell Clin Pharm; 1982 Feb; 16(2):126-31. PubMed ID: 7075463 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]